Yes, this new presentation style is a lot more focussed. I missed the webinar though and can't find it online which is a little disappointing. But have to agree with you that CYP is stupidly cheap. It's the only one with a lot of upside and should get a run if MSB gets their fda approval. MSB still a lot of unwound shorts and a big holder selling. So could be a big bag of nothing for a while, especially given the market size and Japan sales. Unless of course they receive a take over.z and I hope they do. But if they break into the ASX top 300 or 200 there'll be more institutional & index buying. I hold both so I hope it's good news.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)